Search Results

There are 1346 results for: content related to: Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C

  1. You have free access to this content
    Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection

    Hepatology Research

    Volume 44, Issue 14, December 2014, Pages: E360–E367, Mika Miura, Shinya Maekawa, Mitsuaki Sato, Nobutoshi Komatsu, Akihisa Tatsumi, Shinichi Takano, Fumitake Amemiya, Yasuhiro Nakayama, Taisuke Inoue, Minoru Sakamoto and Nobuyuki Enomoto

    Article first published online : 10 APR 2014, DOI: 10.1111/hepr.12316

  2. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy

    Journal of Medical Virology

    Satoshi Yoshimi, Michio Imamura, Eisuke Murakami, Nobuhiko Hiraga, Masataka Tsuge, Yoshiiku Kawakami, Hiroshi Aikata, Hiromi Abe, C. Nelson Hayes, Tamito Sasaki, Hidenori Ochi and Kazuaki Chayama

    Article first published online : 16 JUN 2015, DOI: 10.1002/jmv.24255

  3. You have free access to this content
    Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection

    Alimentary Pharmacology & Therapeutics

    Volume 42, Issue 3, August 2015, Pages: 258–272, C. Bunchorntavakul and K. R. Reddy

    Article first published online : 27 MAY 2015, DOI: 10.1111/apt.13264

  4. You have free access to this content
    Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir

    Hepatology

    Volume 58, Issue 3, September 2013, Pages: 902–911, Fiona McPhee, Dennis Hernandez, Fei Yu, Joseph Ueland, Aaron Monikowski, Arlene Carifa, Paul Falk, Chunfu Wang, Robert Fridell, Timothy Eley, Nannan Zhou and David Gardiner

    Article first published online : 16 JUL 2013, DOI: 10.1002/hep.26388

  5. Current prospects for interferon-free treatment of hepatitis C in 2012

    Journal of Gastroenterology and Hepatology

    Volume 28, Issue 1, January 2013, Pages: 38–45, Catherine AM Stedman

    Article first published online : 19 DEC 2012, DOI: 10.1111/jgh.12028

  6. Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace

    Reviews in Medical Virology

    Volume 25, Issue 4, July 2015, Pages: 254–267, Erik De Clercq

    Article first published online : 4 JUN 2015, DOI: 10.1002/rmv.1842

  7. Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C

    Hepatology Research

    Yoshihide Ueda, Toshimi Kaido, Etsuro Hatano, Shigeru Ohtsuru and Shinji Uemoto

    Article first published online : 27 APR 2015, DOI: 10.1111/hepr.12509

  8. You have free access to this content
    Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

    Hepatology

    Volume 55, Issue 3, March 2012, Pages: 742–748, Kazuaki Chayama, Shoichi Takahashi, Joji Toyota, Yoshiyasu Karino, Kenji Ikeda, Hiroki Ishikawa, Hideaki Watanabe, Fiona McPhee, Eric Hughes and Hiromitsu Kumada

    Article first published online : 30 JAN 2012, DOI: 10.1002/hep.24724

  9. You have free access to this content
    Treatment of hepatitis C virus genotype 3-infection

    Liver International

    Volume 34, Issue s1, February 2014, Pages: 18–23, Stanislas Pol, Anaïs Vallet-Pichard and Marion Corouge

    Article first published online : 23 DEC 2013, DOI: 10.1111/liv.12405

  10. Therapy for hepatitis C genotype 3: moving forward

    Journal of Viral Hepatitis

    Volume 22, Issue 9, September 2015, Pages: 683–690, M. Buti, J. Llaneras, M. Riveiro-Barciela and R. Esteban

    Article first published online : 13 MAY 2015, DOI: 10.1111/jvh.12419

  11. You have free access to this content
    Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir

    Hepatology

    Volume 61, Issue 1, January 2015, Pages: 400–401, Yohei Fujii, Yoshihito Uchida and Satoshi Mochida

    Article first published online : 15 DEC 2014, DOI: 10.1002/hep.27559

  12. Novel Therapeutic Approaches for Hepatitis C

    Clinical Pharmacology & Therapeutics

    Volume 95, Issue 1, January 2014, Pages: 78–88, JS Au and PJ Pockros

    Article first published online : 19 DEC 2013, DOI: 10.1038/clpt.2013.206

  13. You have free access to this content
    Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null responders

    Hepatology

    Volume 57, Issue 5, May 2013, Page: 2087, Enrico Galmozzi, Alessio Aghemo and Massimo Colombo

    Article first published online : 4 FEB 2013, DOI: 10.1002/hep.25924

  14. Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor

    Journal of Pharmaceutical Sciences

    Kathleen W. Mosure, Jay O. Knipe, Marc Browning, Vinod Arora, Yue-Zhong Shu, Thomas Phillip, Fiona Mcphee, Paul Scola, Anand Balakrishnan, Matthew G. Soars, Kenneth Santone and Michael Sinz

    Article first published online : 28 JAN 2015, DOI: 10.1002/jps.24356

  15. The Discovery of Potent Nonstructural Protein 5A (NS5A) Inhibitors with a Unique Resistance Profile—Part 1

    ChemMedChem

    Volume 9, Issue 7, July 2014, Pages: 1378–1386, Thien Duc Tran, Florian Wakenhut, Dr. Chris Pickford, Stephen Shaw, Dr. Mike Westby, Caroline Smith-Burchnell, Lesa Watson, Michael Paradowski, Dr. Jared Milbank, Dr. Rebecca A. Brimage, Rebecca Halstead, Dr. Rebecca Glen, Dr. Craig P. Wilson, Fiona Adam, Duncan Hay, Jean-Yves Chiva, Carly Nichols, Dr. David C. Blakemore, Iain Gardner, Satish Dayal, Dr. Andrew Pike, Rob Webster and Dr. David C. Pryde

    Article first published online : 11 APR 2014, DOI: 10.1002/cmdc.201400045

  16. You have free access to this content
    Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation

    Liver Transplantation

    Volume 18, Issue 9, September 2012, Pages: 1053–1059, Robert J. Fontana, Eric A. Hughes, Henry Appelman, Robert Hindes, Dessislava Dimitrova and Marc Bifano

    Article first published online : 27 AUG 2012, DOI: 10.1002/lt.23482

  17. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C

    Journal of Viral Hepatitis

    J. A. Gutierrez, E. J. Lawitz and F. Poordad

    Article first published online : 17 JUN 2015, DOI: 10.1111/jvh.12422

  18. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1

    Journal of Viral Hepatitis

    Volume 22, Issue 2, February 2015, Pages: 158–165, K. Kosaka, M. Imamura, C. N. Hayes, H. Abe, N. Hiraga, S. Yoshimi, E. Murakami, T. Kawaoka, M. Tsuge, H. Aikata, D. Miki, H. Ochi, H. Matsui, A. Kanai, T. Inaba and K. Chayama

    Article first published online : 19 JUN 2014, DOI: 10.1111/jvh.12271

  19. You have free access to this content
    Poster Session 4: Hepatitis C: New Agents (Not Approved)

    Hepatology

    Volume 60, Issue S1, October 2014, Pages: 1128A–1161A,

    Article first published online : 1 OCT 2014, DOI: 10.1002/hep.27533

  20. You have free access to this content
    How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals

    Liver International

    Volume 35, Issue s1, January 2015, Pages: 18–20, Lawrence Serfaty

    Article first published online : 22 DEC 2014, DOI: 10.1111/liv.12722